Harnessing naturally occurring mutations for T-cell therapy:a potential new avenue to enhance treatment efficacy  

作　　者：Michael Hiltensperger Jürgen Ruland Kilian Schober 

机构地区：[1]Mikrobiologisches Institut-Klinische Mikrobiologie,Immunologie und Hygiene,Friedrich-Alexander-Universität Erlangen-Nürnberg,Erlangen,Germany [2]Institute of Clinical Chemistry and Pathobiochemistry,School of Medicine,Technical University of Munich,Munich,Germany [3]TranslaTUM,Center for Translational Cancer Research,Technical University of Munich,Munich,Germany [4]German Cancer Consortium(DKTK),Heidelberg,Germany [5]German Center for Infection Research(DZIF),partner site Munich,Munich,Germany [6]FAU Profile Center Immunomedicine,Friedrich-Alexander-Universität Erlangen-Nürnberg,Erlangen,Germany

出　　处：《Signal Transduction and Targeted Therapy》2024年第5期1799-1801,共3页信号转导与靶向治疗（英文）

基　　金：K.S.is supported by grants from the German Federal Ministry of Education and Research(BMBF,project-IDs 01KI2013 and 031L0290B);the Else Kröner-Fresenius-Stiftung(project-ID 2020_EKEA.127);the German Research Foundation(DFG)through the research training group RTG 2504(project-ID 401821119);the Interdisciplinary Center for Clinical Research of the University Hospital of Erlangen(project-ID A98);the European Union(Yellow4FLAVI consortium,project-ID 101137459);J.R.is supported by grants from the German Research Foundation(DFG)(project-ID 210592381-SFB 1054,project-ID 395357507-SFB 1371,project-ID 369799452-TRR 237,project-ID 452881907-TRR 338,project-ID 435874434-RTG 2668,RU 695/12-1);The Leukemia&Lymphoma Society,and the European Research Council(ERC)under the European Union’s Horizon 2020 research and innovation programme(grant agreement No 834154).

摘　　要：In a recent study published in Nature,Garcia et al.use a sophisticated approach to identify fitness-enhancing mutations for T cells that was inspired by cancer evolution.1 The identified CARD11-PIK3R3 gene fusion enhanced tumor rejection and persistence of engineered T cells in multiple tumor models and might have the potential to improve efficacy of adoptive T-cell therapies in cancer patients.

关 键 词：cancer POTENTIAL 

分 类 号：R329.2[医药卫生—人体解剖和组织胚胎学]